Program Objectives
Obtain funding for drug scale up and rodent/dog toxicity study
Complete CBT300 drug product with GLP/GMP
Determine CBT300 safety profile in rodents and non-human primates
Prepare for Investigative New Drug Application
Validate CBT300 in Phase I clinical trial
Current Objectives
Current Status | Accomplishments
CBT is focusing on the development of its lead therapy CBT300 for the treatment of late stage, drug resistant and deadly viruses and cancers
CBT has established a beachhead target for cancer in Metastatic Breast Cancer
CBT will continue evaluate the market for late-stage COVID and Long COVID with a potential combined Phase I clinical trial in patients with both cancer and COVID in the hospital
CBT has selected and successfully integrated several top tier CROs for Proof of Concept studies, Drug Development, Drug Manufacturing, Regulatory and Clinical Trials.
CBT has assembled an excellent Board of Advisors for business and technical support
CBT has initiated seating of a formal Board of Directors
CBT has developed CBT300 in parallel for as both an anti-viral and anti-cancer exploiting the advantage of a similar mechanism of action
CBT has completed Proof of Concept, In Vitro Safety profiles, Development of drug manufacturing for scale up
2023/24
Secure Series A funding of $10M for GMP/GLP drug scale up to perform Rat Toxicity followed by Pre-IND/IND with the FDA
Perform Phase I clinical trials in drug resistant Breast Cancer
2025/26
Secure additional Series B funding of $15-25M for GMP drug production, Dog Toxicity, and Phase II clinical trial
Market entry for Metastatic Breast Cancer pending market need